Entrada's ENTR-601-44 Delivers Positive Phase 1/2 DMD Results, Showing Statistically Significant Functional Gains
TRDA has more than doubled off its 52-week low of $4.93 on elevated volume (2.0× avg).
Summary
Entrada Therapeutics announced positive topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 study for ENTR-601-44 in Duchenne Muscular Dystrophy (DMD). The study demonstrated a favorable safety profile with no serious adverse events and normal kidney function markers. Crucially, treated participants showed a statistically significant and potentially differentiated improvement in Time to Rise velocity, a clinically validated functional measurement. These positive Phase 1/2 results, particularly the functional improvement, are highly material for Entrada Therapeutics, validating its lead investigational product and de-risking its DMD franchise. The company also provided a clear explanation for lower plasma exposure in juveniles and outlined plans for Cohort 2 at a higher dose (12 mg/kg), which is predicted to lead to substantially higher dystrophin levels and continued functional benefits. Investors will now focus on the upcoming data from the Cohort 1 open-label study and Cohort 2 MAD study, expected by year-end 2026, which could further solidify the drug's potential and drive future stock performance.
At the time of this announcement, TRDA was trading at $15.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $622.3M. The 52-week trading range was $4.93 to $16.45. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.